Which has preferable valuation and earnings, ALKS or GERN?

Alkermes has higher revenue and earnings than Geron. Geron is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alkermes $1.48B 5.59 $241.66M $0.38 129.39 Geron $183.88M 5.17 -$83.50M -$0.11 N/A

Is ALKS or GERN more profitable?

Alkermes has a net margin of 3.96% compared to Geron's net margin of -34.17%. Alkermes' return on equity of 4.15% beat Geron's return on equity. Company Net Margins Return on Equity Return on Assets Alkermes 3.96% 4.15% 2.19% Geron -34.17% -24.48% -10.30%

Does the media refer more to ALKS or GERN?

In the previous week, Geron had 1 more articles in the media than Alkermes. MarketBeat recorded 22 mentions for Geron and 21 mentions for Alkermes. Alkermes' average media sentiment score of 0.40 beat Geron's score of -0.16 indicating that Alkermes is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alkermes 13 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Geron 4 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has higher valuation and earnings, GERN or TNGX?

Geron has higher revenue and earnings than Tango Therapeutics. Tango Therapeutics is trading at a lower price-to-earnings ratio than Geron, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Geron $183.88M 5.17 -$83.50M -$0.11 N/A Tango Therapeutics $62.38M 62.77 -$101.59M -$0.83 N/A

Is GERN or TNGX more profitable?

Tango Therapeutics has a net margin of 0.00% compared to Geron's net margin of -34.17%. Geron's return on equity of -24.48% beat Tango Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Geron -34.17% -24.48% -10.30% Tango Therapeutics N/A -41.54% -33.44%

Does the media favor GERN or TNGX?

In the previous week, Geron had 14 more articles in the media than Tango Therapeutics. MarketBeat recorded 22 mentions for Geron and 8 mentions for Tango Therapeutics. Tango Therapeutics' average media sentiment score of 0.81 beat Geron's score of -0.16 indicating that Tango Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Geron 4 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Tango Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings & valuation, GERN or PBLS?

Parabilis Medicines has lower revenue, but higher earnings than Geron. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Geron $183.88M 5.17 -$83.50M -$0.11 N/A Parabilis Medicines N/A N/A N/A N/A N/A

Does the media refer more to GERN or VKTX?

In the previous week, Geron had 9 more articles in the media than Viking Therapeutics. MarketBeat recorded 22 mentions for Geron and 13 mentions for Viking Therapeutics. Viking Therapeutics' average media sentiment score of 1.05 beat Geron's score of -0.16 indicating that Viking Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Geron 4 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Viking Therapeutics 9 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to GERN or DNLI?

In the previous week, Geron had 11 more articles in the media than Denali Therapeutics. MarketBeat recorded 22 mentions for Geron and 11 mentions for Denali Therapeutics. Denali Therapeutics' average media sentiment score of 0.27 beat Geron's score of -0.16 indicating that Denali Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Geron 4 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Denali Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Geron (GERN) Competitors

$1.48 -0.09 (-5.73%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$1.48 +0.01 (+0.34%)

As of 08/7/2026 07:58 PM Eastern

Compare

GERN vs. ALKS, TNGX, PBLS, VKTX, and DNLI

Should you buy Geron stock or one of its competitors? MarketBeat compares Geron with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Geron include Alkermes (ALKS), Tango Therapeutics (TNGX), Parabilis Medicines (PBLS), Viking Therapeutics (VKTX), and Denali Therapeutics (DNLI). These companies are all part of the "healthcare" sector.

How does Geron compare to Alkermes?

Alkermes (NASDAQ:ALKS) and Geron (NASDAQ:GERN) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, valuation, risk, analyst recommendations, earnings, dividends and profitability.

Alkermes has a beta of 0.34, meaning that its stock price is 66% less volatile than the broader market. Comparatively, Geron has a beta of 0.61, meaning that its stock price is 39% less volatile than the broader market.

Alkermes has higher revenue and earnings than Geron. Geron is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alkermes	$1.48B	5.59	$241.66M	$0.38	129.39
Geron	$183.88M	5.17	-$83.50M	-$0.11	N/A

Alkermes has a net margin of 3.96% compared to Geron's net margin of -34.17%. Alkermes' return on equity of 4.15% beat Geron's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alkermes	3.96%	4.15%	2.19%
Geron	-34.17%	-24.48%	-10.30%

Alkermes currently has a consensus target price of $54.56, indicating a potential upside of 10.97%. Geron has a consensus target price of $4.00, indicating a potential upside of 170.27%. Given Geron's higher possible upside, analysts plainly believe Geron is more favorable than Alkermes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alkermes	1 Sell rating(s)	4 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.72
Geron	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

95.2% of Alkermes shares are held by institutional investors. Comparatively, 73.7% of Geron shares are held by institutional investors. 4.6% of Alkermes shares are held by insiders. Comparatively, 1.7% of Geron shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Geron had 1 more articles in the media than Alkermes. MarketBeat recorded 22 mentions for Geron and 21 mentions for Alkermes. Alkermes' average media sentiment score of 0.40 beat Geron's score of -0.16 indicating that Alkermes is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alkermes	13 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Geron	4 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

Alkermes beats Geron on 14 of the 17 factors compared between the two stocks.

How does Geron compare to Tango Therapeutics?

Geron (NASDAQ:GERN) and Tango Therapeutics (NASDAQ:TNGX) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, earnings, profitability, risk, media sentiment and valuation.

Geron currently has a consensus price target of $4.00, indicating a potential upside of 170.27%. Tango Therapeutics has a consensus price target of $42.15, indicating a potential upside of 55.72%. Given Geron's higher possible upside, equities research analysts plainly believe Geron is more favorable than Tango Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Geron	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Tango Therapeutics	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75

Tango Therapeutics has a net margin of 0.00% compared to Geron's net margin of -34.17%. Geron's return on equity of -24.48% beat Tango Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Geron	-34.17%	-24.48%	-10.30%
Tango Therapeutics	N/A	-41.54%	-33.44%

Geron has higher revenue and earnings than Tango Therapeutics. Tango Therapeutics is trading at a lower price-to-earnings ratio than Geron, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Geron	$183.88M	5.17	-$83.50M	-$0.11	N/A
Tango Therapeutics	$62.38M	62.77	-$101.59M	-$0.83	N/A

73.7% of Geron shares are owned by institutional investors. Comparatively, 79.0% of Tango Therapeutics shares are owned by institutional investors. 1.7% of Geron shares are owned by company insiders. Comparatively, 6.5% of Tango Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Geron had 14 more articles in the media than Tango Therapeutics. MarketBeat recorded 22 mentions for Geron and 8 mentions for Tango Therapeutics. Tango Therapeutics' average media sentiment score of 0.81 beat Geron's score of -0.16 indicating that Tango Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Geron	4 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Tango Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Geron has a beta of 0.61, suggesting that its stock price is 39% less volatile than the broader market. Comparatively, Tango Therapeutics has a beta of 1.16, suggesting that its stock price is 16% more volatile than the broader market.

Summary

Geron and Tango Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Geron compare to Parabilis Medicines?

Geron (NASDAQ:GERN) and Parabilis Medicines (NASDAQ:PBLS) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, media sentiment, profitability, risk, earnings and dividends.

Parabilis Medicines has a net margin of 0.00% compared to Geron's net margin of -34.17%. Parabilis Medicines' return on equity of 0.00% beat Geron's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Geron	-34.17%	-24.48%	-10.30%
Parabilis Medicines	N/A	N/A	N/A

73.7% of Geron shares are owned by institutional investors. 1.7% of Geron shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Parabilis Medicines has lower revenue, but higher earnings than Geron.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Geron	$183.88M	5.17	-$83.50M	-$0.11	N/A
Parabilis Medicines	N/A	N/A	N/A	N/A	N/A

In the previous week, Geron had 22 more articles in the media than Parabilis Medicines. MarketBeat recorded 22 mentions for Geron and 0 mentions for Parabilis Medicines. Parabilis Medicines' average media sentiment score of 1.34 beat Geron's score of -0.16 indicating that Parabilis Medicines is being referred to more favorably in the news media.

Company	Overall Sentiment
Geron	Neutral
Parabilis Medicines	Positive

Geron presently has a consensus target price of $4.00, indicating a potential upside of 170.27%. Parabilis Medicines has a consensus target price of $41.67, indicating a potential upside of 19.12%. Given Geron's higher probable upside, research analysts clearly believe Geron is more favorable than Parabilis Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Geron	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Parabilis Medicines	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	3.00

Summary

Parabilis Medicines beats Geron on 7 of the 12 factors compared between the two stocks.

How does Geron compare to Viking Therapeutics?

Geron (NASDAQ:GERN) and Viking Therapeutics (NASDAQ:VKTX) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, valuation, profitability, dividends, earnings and media sentiment.

Geron currently has a consensus price target of $4.00, indicating a potential upside of 170.27%. Viking Therapeutics has a consensus price target of $97.88, indicating a potential upside of 185.68%. Given Viking Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Viking Therapeutics is more favorable than Geron.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Geron	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Viking Therapeutics	2 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.67

Viking Therapeutics has a net margin of 0.00% compared to Geron's net margin of -34.17%. Geron's return on equity of -24.48% beat Viking Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Geron	-34.17%	-24.48%	-10.30%
Viking Therapeutics	N/A	-94.56%	-82.75%

Geron has higher revenue and earnings than Viking Therapeutics. Geron is trading at a lower price-to-earnings ratio than Viking Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Geron	$183.88M	5.17	-$83.50M	-$0.11	N/A
Viking Therapeutics	N/A	N/A	-$359.64M	-$4.66	N/A

In the previous week, Geron had 9 more articles in the media than Viking Therapeutics. MarketBeat recorded 22 mentions for Geron and 13 mentions for Viking Therapeutics. Viking Therapeutics' average media sentiment score of 1.05 beat Geron's score of -0.16 indicating that Viking Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Geron	4 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Viking Therapeutics	9 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Geron has a beta of 0.61, suggesting that its share price is 39% less volatile than the broader market. Comparatively, Viking Therapeutics has a beta of 0.69, suggesting that its share price is 31% less volatile than the broader market.

73.7% of Geron shares are owned by institutional investors. Comparatively, 76.0% of Viking Therapeutics shares are owned by institutional investors. 1.7% of Geron shares are owned by company insiders. Comparatively, 5.3% of Viking Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Viking Therapeutics beats Geron on 10 of the 16 factors compared between the two stocks.

How does Geron compare to Denali Therapeutics?

Geron (NASDAQ:GERN) and Denali Therapeutics (NASDAQ:DNLI) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings and valuation.

Geron presently has a consensus target price of $4.00, indicating a potential upside of 170.27%. Denali Therapeutics has a consensus target price of $35.92, indicating a potential upside of 44.65%. Given Geron's higher possible upside, equities analysts plainly believe Geron is more favorable than Denali Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Geron	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Denali Therapeutics	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75

Denali Therapeutics has a net margin of 0.00% compared to Geron's net margin of -34.17%. Geron's return on equity of -24.48% beat Denali Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Geron	-34.17%	-24.48%	-10.30%
Denali Therapeutics	N/A	-53.53%	-44.26%

Geron has a beta of 0.61, suggesting that its share price is 39% less volatile than the broader market. Comparatively, Denali Therapeutics has a beta of 1.01, suggesting that its share price is 1% more volatile than the broader market.

73.7% of Geron shares are owned by institutional investors. Comparatively, 92.9% of Denali Therapeutics shares are owned by institutional investors. 1.7% of Geron shares are owned by insiders. Comparatively, 9.7% of Denali Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Geron has higher earnings, but lower revenue than Denali Therapeutics. Geron is trading at a lower price-to-earnings ratio than Denali Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Geron	$183.88M	5.17	-$83.50M	-$0.11	N/A
Denali Therapeutics	$330.53M	11.92	-$512.54M	-$2.88	N/A

In the previous week, Geron had 11 more articles in the media than Denali Therapeutics. MarketBeat recorded 22 mentions for Geron and 11 mentions for Denali Therapeutics. Denali Therapeutics' average media sentiment score of 0.27 beat Geron's score of -0.16 indicating that Denali Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Geron	4 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Denali Therapeutics	3 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Denali Therapeutics beats Geron on 10 of the 16 factors compared between the two stocks.

Get Geron News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GERN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GERN vs. The Competition

Export

Metric	Geron	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.01B	$3.62B	$6.92B	$12.87B
Dividend Yield	N/A	3.77%	2.59%	9.91%
P/E Ratio	-13.45	9.03	271.39	25.24
Price / Sales	5.17	1,274.65	598.32	98.55
Price / Cash	N/A	98.58	71.46	49.72
Price / Book	4.35	18.10	13.25	6.22
Net Income	-$83.50M	-$13.25M	$3.45B	$342.66M
7 Day Performance	14.73%	6.24%	4.67%	4.41%
1 Month Performance	-5.13%	-2.70%	-0.79%	-0.28%
1 Year Performance	15.63%	61.17%	76.94%	22.60%

Geron Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GERN Geron	2.1782 of 5 stars	$1.48 -5.7%	$4.00 +170.3%	+13.8%	$1.01B	$183.88M	N/A	70	Trending News Earnings Report Options Volume Analyst Revision
ALKS Alkermes	3.057 of 5 stars	$48.37 -2.5%	$54.56 +12.8%	+84.9%	$8.32B	$1.67B	127.29	2,050
TNGX Tango Therapeutics	2.5228 of 5 stars	$29.00 +0.7%	$42.15 +45.4%	+309.5%	$4.16B	$62.38M	N/A	90	Upcoming Earnings
PBLS Parabilis Medicines	3.3077 of 5 stars	$35.58 +1.9%	$41.67 +17.1%	N/A	$4.12B	N/A	N/A	N/A	Positive News
VKTX Viking Therapeutics	3.5201 of 5 stars	$33.30 -0.6%	$97.88 +193.9%	-3.7%	$3.91B	N/A	N/A	20

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GERN) was last updated on 8/8/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Geron (GERN) Competitors

GERN vs. ALKS, TNGX, PBLS, VKTX, and DNLI

How does Geron compare to Alkermes?

Summary

How does Geron compare to Tango Therapeutics?

Summary

How does Geron compare to Parabilis Medicines?

Summary

How does Geron compare to Viking Therapeutics?

Summary

How does Geron compare to Denali Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GERN vs. The Competition

Geron Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Geron (GERN) Competitors

GERN vs. ALKS, TNGX, PBLS, VKTX, and DNLI

How does Geron compare to Alkermes?

Which has more volatility & risk, ALKS or GERN?

Which has preferable valuation and earnings, ALKS or GERN?

Is ALKS or GERN more profitable?

Do analysts rate ALKS or GERN?

Do institutionals and insiders have more ownership in ALKS or GERN?

Does the media refer more to ALKS or GERN?

Summary

How does Geron compare to Tango Therapeutics?

Do analysts rate GERN or TNGX?

Is GERN or TNGX more profitable?

Which has higher valuation and earnings, GERN or TNGX?

Do institutionals & insiders believe in GERN or TNGX?

Does the media favor GERN or TNGX?

Which has more volatility and risk, GERN or TNGX?

Summary

How does Geron compare to Parabilis Medicines?

Is GERN or PBLS more profitable?

Do insiders & institutionals believe in GERN or PBLS?

Which has preferable earnings & valuation, GERN or PBLS?

Does the media favor GERN or PBLS?

Do analysts rate GERN or PBLS?

Summary

How does Geron compare to Viking Therapeutics?

Do analysts rate GERN or VKTX?

Is GERN or VKTX more profitable?

Which has stronger valuation & earnings, GERN or VKTX?

Does the media refer more to GERN or VKTX?

Which has more volatility & risk, GERN or VKTX?

Do insiders and institutionals believe in GERN or VKTX?

Summary

How does Geron compare to Denali Therapeutics?

Do analysts rate GERN or DNLI?

Is GERN or DNLI more profitable?

Which has more volatility and risk, GERN or DNLI?

Do insiders & institutionals believe in GERN or DNLI?

Which has better valuation and earnings, GERN or DNLI?

Does the media refer more to GERN or DNLI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GERN vs. The Competition

Geron Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools